Annual SGA
$45.26 M
-$6.38 M-12.36%
December 31, 2022
Summary
- As of February 10, 2025, NBRV annual SGA is $45.26 million, with the most recent change of -$6.38 million (-12.36%) on December 31, 2022.
- During the last 3 years, NBRV annual SGA has fallen by -$17.22 million (-27.56%).
Performance
NBRV SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly SGA
$9.00 M
-$608.00 K-6.33%
March 31, 2023
Summary
- As of February 10, 2025, NBRV quarterly SGA is $9.00 million, with the most recent change of -$608.00 thousand (-6.33%) on March 31, 2023.
- Over the past year, NBRV quarterly SGA has dropped by -$3.70 million (-29.12%).
Performance
NBRV Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM SGA
-$2.56 B
-$54.07 M-2.15%
March 31, 2023
Summary
- As of February 10, 2025, NBRV TTM SGA is -$2.56 billion, with the most recent change of -$54.07 million (-2.15%) on March 31, 2023.
- Over the past year, NBRV TTM SGA has dropped by -$2.62 billion (-5000.90%).
Performance
NBRV TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
NBRV Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -12.4% | -29.1% | -5000.9% |
| 3 y3 years | -27.6% | -43.8% | -4037.1% |
| 5 y5 years | +53.6% | -11.2% | -4201.9% |
NBRV Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -12.4% | at low | -37.9% | at low | +10.9% | at low |
| 5 y | 5-year | -27.6% | at low | -48.6% | at low | +43.9% | at low |
| alltime | all time | -27.6% | -91.8% | -51.3% | -93.1% | +2075.1% | at low |
Nabriva Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | $9.00 M(-6.3%) | $41.57 M(-8.2%) |
| Dec 2022 | $45.26 M(-12.4%) | $9.61 M(-19.3%) | $45.26 M(-9.7%) |
| Sep 2022 | - | $11.91 M(+7.8%) | $50.14 M(-0.7%) |
| Jun 2022 | - | $11.05 M(-13.0%) | $50.49 M(-3.5%) |
| Mar 2022 | - | $12.70 M(-12.3%) | $52.30 M(+1.3%) |
| Dec 2021 | $51.65 M(-6.6%) | $14.49 M(+18.2%) | $51.65 M(-5.5%) |
| Sep 2021 | - | $12.26 M(-4.7%) | $54.68 M(+2.4%) |
| Jun 2021 | - | $12.85 M(+6.7%) | $53.42 M(+4.1%) |
| Mar 2021 | - | $12.05 M(-31.2%) | $51.31 M(-7.2%) |
| Dec 2020 | $55.28 M(-11.5%) | $17.52 M(+59.3%) | $55.28 M(+0.7%) |
| Sep 2020 | - | $11.00 M(+2.4%) | $54.91 M(-12.0%) |
| Jun 2020 | - | $10.74 M(-33.0%) | $62.41 M(-4.1%) |
| Mar 2020 | - | $16.02 M(-6.5%) | $65.10 M(+4.2%) |
| Dec 2019 | $62.48 M(+49.7%) | $17.15 M(-7.3%) | $62.48 M(+12.5%) |
| Sep 2019 | - | $18.50 M(+37.8%) | $55.53 M(+11.9%) |
| Jun 2019 | - | $13.43 M(+0.1%) | $49.61 M(+10.2%) |
| Mar 2019 | - | $13.41 M(+31.6%) | $45.02 M(+7.8%) |
| Dec 2018 | $41.74 M | $10.19 M(-19.0%) | $41.74 M(+0.1%) |
| Sep 2018 | - | $12.58 M(+42.4%) | $41.71 M(+7.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | - | $8.84 M(-12.8%) | $38.66 M(+9.2%) |
| Mar 2018 | - | $10.14 M(-0.2%) | $35.39 M(+20.1%) |
| Dec 2017 | $29.47 M(+117.7%) | $10.16 M(+6.7%) | $29.47 M(+25.9%) |
| Sep 2017 | - | $9.53 M(+71.0%) | $23.40 M(+38.7%) |
| Jun 2017 | - | $5.57 M(+32.1%) | $16.87 M(+15.2%) |
| Mar 2017 | - | $4.22 M(+3.1%) | $14.65 M(+8.5%) |
| Dec 2016 | $13.54 M(+70.9%) | $4.09 M(+36.7%) | $13.50 M(+3.8%) |
| Sep 2016 | - | $2.99 M(-10.6%) | $13.00 M(+10.3%) |
| Jun 2016 | - | $3.35 M(+9.0%) | $11.79 M(+16.9%) |
| Mar 2016 | - | $3.07 M(-14.7%) | $10.09 M(+27.3%) |
| Dec 2015 | $7.92 M(+114.4%) | $3.60 M(+102.5%) | $7.92 M(+32.8%) |
| Sep 2015 | - | $1.78 M(+8.0%) | $5.97 M(+24.0%) |
| Jun 2015 | - | $1.65 M(+82.0%) | $4.81 M(+24.7%) |
| Mar 2015 | - | $904.00 K(-44.9%) | $3.86 M(+4.4%) |
| Dec 2014 | $3.69 M(-5.6%) | $1.64 M(+164.4%) | $3.69 M(+79.9%) |
| Sep 2014 | - | $620.50 K(-10.4%) | $2.05 M(+43.3%) |
| Jun 2014 | - | $692.60 K(-6.6%) | $1.43 M(+93.4%) |
| Mar 2014 | - | $741.30 K | $741.30 K |
| Dec 2013 | $3.91 M | - | - |
FAQ
- What is Nabriva Therapeutics annual SGA?
- What is the all time high annual SGA for Nabriva Therapeutics?
- What is Nabriva Therapeutics annual SGA year-on-year change?
- What is Nabriva Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Nabriva Therapeutics?
- What is Nabriva Therapeutics quarterly SGA year-on-year change?
- What is Nabriva Therapeutics TTM SGA?
- What is the all time high TTM SGA for Nabriva Therapeutics?
- What is Nabriva Therapeutics TTM SGA year-on-year change?
What is Nabriva Therapeutics annual SGA?
The current annual SGA of NBRV is $45.26 M
What is the all time high annual SGA for Nabriva Therapeutics?
Nabriva Therapeutics all-time high annual SGA is $62.48 M
What is Nabriva Therapeutics annual SGA year-on-year change?
Over the past year, NBRV annual SGA has changed by -$6.38 M (-12.36%)
What is Nabriva Therapeutics quarterly SGA?
The current quarterly SGA of NBRV is $9.00 M
What is the all time high quarterly SGA for Nabriva Therapeutics?
Nabriva Therapeutics all-time high quarterly SGA is $18.50 M
What is Nabriva Therapeutics quarterly SGA year-on-year change?
Over the past year, NBRV quarterly SGA has changed by -$3.70 M (-29.12%)
What is Nabriva Therapeutics TTM SGA?
The current TTM SGA of NBRV is -$2.56 B
What is the all time high TTM SGA for Nabriva Therapeutics?
Nabriva Therapeutics all-time high TTM SGA is -$117.84 M
What is Nabriva Therapeutics TTM SGA year-on-year change?
Over the past year, NBRV TTM SGA has changed by -$2.62 B (-5000.90%)